Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183355 | 0.85 | DYRK1A (0.37) | DYRK1AKEAP1NAMPTMEN1CYP1A2 | |
| SCHEMBL24574341 | 0.83 | NAMPT (0.34) | DYRK1AKEAP1NAMPTMEN1CYP1A2 | |
| SCHEMBL19969731 | 0.79 | KEAP1 (0.37) | DYRK1AKEAP1NAMPTMEN1CYP1A2 | |
| SCHEMBL29837274 | 0.78 | NAMPT (0.40) | DYRK1AKEAP1NAMPTMEN1CYP1A2 | |
| SCHEMBL19969788 | 0.77 | KEAP1 (0.35) | DYRK1AKEAP1NAMPTMEN1CYP1A2 | |
| SCHEMBL22726755 | 0.73 | SSTR4 (0.33) | SSTR4 | |
| SCHEMBL2629380 | 0.72 | TGFBR1 (0.43) | DYRK1AKEAP1NAMPTMEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL30804022 | 0.72 | NAMPT (0.42) | NAMPTMEN1CYP1A2KMT2AMCHR1 | |
| SCHEMBL19950935 | 0.71 | SSTR4 (0.49) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL5487376 | 0.71 | DYRK1A (0.40) | DYRK1AKEAP1NAMPTMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| WO-2023250431-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240294530-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2024-09-05 | — | — | US | disclosed |
| WO-2022140647-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294530-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | DYRK1A 631/4885KEAP1 1161/4885NAMPT 2457/4885 |
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | FLT3, IRAK3, IRAK2 | DYRK1A 1980/4885KEAP1 1096/4885NAMPT 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.